Copayment level and drug switching: Findings for type 2 diabetes

American Journal of Pharmacy Benefits

Volumn 2, Issue 7, 2010, Pages 412-420

  Saito, Erin P ^a   Davis, James W ^a   Harrigan, Rosanne C ^a   Juarez, Debora ^b   Mau, Marjorie K ^a  

^a UNIVERSITY OF HAWAII   (United States)

^b Hawaii Medical Service Association   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BIGUANIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; INSULIN; MEGLITINIDE; SULFONYLUREA;

ADULT; AGED; ARTICLE; CHINESE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA ANALYSIS; DEMOGRAPHY; DRUG COST; DRUG SUBSTITUTION; DRUG USE; FEMALE; FILIPINO; GLYCEMIC CONTROL; HAZARD RATIO; HEALTH INSURANCE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PACIFIC ISLANDER; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SOCIAL ASPECT;

EID: 78751640382     PISSN: 19454481     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Gibson TB, Ozminkowski RJ, Goetzel RZ. The effects of prescription drug cost sharing: a review of the evidence. Am J Manag Care. 2005;11(11):730-740.
2. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007; 298(1):61-69.
3. Motheral B, Fairman KA. Effect of a three-tier prescription copay on pharmaceutical and other medical utilization. Med Care. 2001;39(12):1293-1304.
4. Nair KV, Wolfe P, Valuck RJ, McCollum MM, Ganther JM, Lewis SJ. Effects of a 3-tier pharmacy benefit design on the prescription purchasing behavior of individuals with chronic disease. J Manag Care Pharm. 2003;9(2):123-133.
5. Roblin DW, Platt R, Goodman MJ, et al. Effect of increased cost-sharing on oral hypoglycemic use in five managed care organizations: how much is too much? Med Care. 2005;43(10):951-959.
6. Tseng CW, Tierney EF, Gerzoff RB, et al. Race/ethnicity and economic differences in cost-related medication underuse among insured adults with diabetes: the Translating Research Into Action for Diabetes Study. Diabetes Care. 2008;31(2):261-266.
7. Wilson J, Axelsen K, Tang S. Medicaid prescription drug access restrictions: exploring the effect on patient persistence with hypertension medications. Am J Manag Care. 2005;11(Spec No):SP27-SP34.
8. Tseng CW, Brook RH, Keeler E, Steers WN, Waitzfelder BE, Mangione CM. Effect of generic-only drug benefits on seniors' medication use and financial burden. Am J Manag Care. 2006;12(9):525-532.
9. Cox ER, Jernigan C, Coons SJ, Draugalis JL. Medicare beneficiaries' management of capped prescription benefits. Med Care. 2001;39(3):296-301.
10. Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Frank RG. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med. 2003;349(23):2224-2232.
11. Rector TS, Finch MD, Danzon PM, Pauly MV, Manda BS. Effect of tiered prescription copayments on the use of preferred brand medications. Med Care. 2003;41(3):398-406.
12. Schneeweiss S, Soumerai SB, Glynn RJ, Maclure M, Dormuth C, Walker AM. Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization. CMAJ. 2002;166(6):737-745.
13. Briesacher BA, Limcangco MR, Frech-Tamas F. New-user persistence with antihypertensives and prescription drug cost-sharing. J Clin Hypertens (Greenwich). 2007;9(11):831-836.
14. Taira DA, Wong KS, Frech-Tamas F, Chung RS. Copayment level and compliance with antihypertensive medication: analysis and policy implications for managed care. Am J Manag Care. 2006;12(11):678-683.
15. American Diabetes Association. Economic costs of diabetes in the U.S. in 2007 [published correction appears in Diabetes Care. 2008;31(6):1271]. Diabetes Care. 2008;31(3):596-615.
16. Hawaii Department of Health, Centers for Disease Control and Prevention. Behavioral risk factor surveillance system, 2006. http://healthuser.hawaii.gov/health/statistics/brfss/index.html. Accessed February 22, 2008.
17. National Diabetes Information Clearinghouse (NDIC). National diabetes statistics, 2007. http://diabetes.niddk.nih.gov/dm/pubs/statistics/index.htm. Accessed February 22, 2008.
18. Goldman DP, Joyce GF, Escarce JJ, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA. 2004;291(19):2344-2350.
19. Heisler M, Wagner TH, Piette JD. Clinician identification of chronically ill patients who have problems paying for prescription medications. Am J Med. 2004;116(11):753-758.
20. Tseng CW, Dudley RA, Brook RH, et al. Elderly patients' preferences and experiences with providers in managing their drug costs. J Am Geriatr Soc. 2007;55(12):1974-1980.
21. Piette JD, Heisler M, Horne R, Caleb Alexander G. A conceptually based approach to understanding chronically ill patients' responses to medication cost pressures. Soc Sci Med. 2006;62(4):846-857.
22. Clark DO, Von Korff M, Saunders K, Baluch WM, Simon GE. A chronic disease score with empirically derived weights. Med Care. 1995;33(8):783-795.
23. McCombs JS, Shi L, Stimmel GL, Croghan TW. A retrospective analysis of the revocation of prior authorization restrictions and the use of antidepressant medications for treating major depressive disorder. Clin Ther. 2002;24(11):1939-1959.
24. Andersen PK, Keiding N. Multistate models for event history analysis. Stat Methods Med Res. 2002;11(2):91-115.
25. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med. 2007;26(11):2389-2430.
26. Hawaii Department of Health. Hawaii Health Survey, 2007. http://hawaii.gov/health/statistics/hhs/index.html. Accessed July 13, 2009.
27. Fairman KA, Motheral BR, Henderson RR. Retrospective, long-term followup study of the effect of a three-tier prescription drug copayment system on pharmaceutical and other medical utilization and costs. Clin Ther. 2003;25(12): 3147-3161.
28. Landon BE, Rosenthal MB, Normand SL, et al. Incentive formularies and changes in prescription drug spending. Am J Manag Care. 2007;13(6 pt 2): 360-369.
29. Motheral BR, Henderson R. The effect of a copay increase on pharmaceutical utilization, expenditures, and treatment continuation. Am J Manag Care. 1999;5(11):1383-1394.
30. Tseng CW, Brook RH, Keeler E, Steers WN, Mangione CM. Cost-lowering strategies used by medicare beneficiaries who exceed drug benefit caps and have a gap in drug coverage. JAMA. 2004;292(8):952-960.
31. Harris BL, Stergachis A, Ried LD. The effect of drug co-payments on utilization and cost of pharmaceuticals in a health maintenance organization. Med Care. 1990;28(10):907-917.
32. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes [published correction appears in Diabetes Care. 2006;29(11):2816-2818]. Diabetes Care. 2006;29(8):1963-1972.
33. Ganther-Urmie JM, Nair KV, Valuck R, McCollum M, Lewis SJ, Turpin RS. Consumer attitudes and factors related to prescription switching decisions in multitier copayment drug benefit plans. Am J Manag Care. 2004;10(3):201-208.
34. Steinman MA, Sands LP, Covinsky KE. Self-restriction of medications due to cost in seniors without prescription coverage. J Gen Intern Med. 2001;16(12): 793-799.
35. Mau MK, West MR, Shara NM, et al. Epidemiologic and clinical factors associated with chronic kidney disease among Asian Americans and Native Hawaiians. Ethn Health. 2007;12(2):111-127.
36. Huskamp HA, Deverka PA, Epstein AM, et al. Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children. Arch Gen Psychiatry. 2005;62(4):435-441.